Valsartan is a blood pressure medication approved for three conditions: high blood pressure, heart failure, and protecting the heart after a heart attack. It belongs to a class of drugs called angiotensin receptor blockers (ARBs), which work by relaxing blood vessels so your heart doesn’t have to pump as hard.
How Valsartan Works
Your body naturally produces a hormone called angiotensin II that tightens blood vessels, particularly the smaller arteries. This tightening increases the resistance your heart has to push against with every beat, which directly raises blood pressure. Valsartan blocks the receptor where angiotensin II docks on blood vessel walls, preventing that tightening signal from going through. The result is lower resistance in your arteries and a measurable drop in blood pressure, both in the short term and with ongoing use.
High Blood Pressure
The primary reason valsartan is prescribed is to lower blood pressure in adults and children aged one year and older. It’s taken once or twice daily as a tablet and is often used alone or combined with other blood pressure medications. For many people, it’s a straightforward, well-tolerated option for keeping blood pressure in a healthy range and reducing the long-term risk of stroke, heart attack, and kidney damage that uncontrolled hypertension carries.
One practical advantage valsartan has over an older class of blood pressure drugs, ACE inhibitors (medications like lisinopril or enalapril), is a lower risk of dry cough. A large multinational study found that ACE inhibitors carried about a 32% higher risk of cough compared to ARBs like valsartan. That persistent, nagging cough is one of the most common reasons people stop taking ACE inhibitors, so valsartan is frequently prescribed as an alternative for people who can’t tolerate them.
Heart Failure
Valsartan is also approved to reduce the risk of hospitalization in adults with heart failure. In heart failure, the heart can’t pump blood efficiently enough to meet the body’s needs. The body responds by producing more angiotensin II to raise blood pressure and compensate, but over time this extra strain makes things worse. Blocking that cycle with valsartan helps reduce the workload on a struggling heart.
For heart failure, treatment typically starts at a low dose of 40 mg taken twice daily. Your doctor will gradually increase the dose over weeks, aiming for up to 160 mg twice daily if you tolerate it well. This slow ramp-up matters because valsartan can cause dizziness and low blood pressure, especially early on. In clinical trials, 17% of people with heart failure taking valsartan experienced dizziness (compared to 9% on placebo), and 7% experienced episodes of low blood pressure (compared to 2% on placebo).
After a Heart Attack
The third approved use is for adults who have survived a heart attack and have signs that their heart isn’t pumping as strongly as it should. In this setting, valsartan is prescribed to lower the risk of dying from cardiovascular causes. The landmark VALIANT trial, which compared valsartan head-to-head with the ACE inhibitor captopril in heart attack survivors, found that valsartan was equally effective at reducing death and other serious cardiovascular events across all age groups. Combining the two drugs offered no additional benefit over either one alone, so valsartan serves as a solid alternative for people who can’t tolerate ACE inhibitors after a heart attack.
Common Side Effects
Most people tolerate valsartan well, particularly when it’s used for blood pressure alone. The side effects that do occur tend to be more noticeable in people taking it for heart failure, where the doses are higher and the heart is already compromised. Dizziness and lightheadedness, especially when standing up quickly, are the most frequently reported issues. Some people also experience changes in kidney function. In heart failure trials, significant increases in blood urea nitrogen (a marker of kidney stress) showed up in about 17% of people on valsartan versus 6% on placebo. Your doctor will monitor your kidney function with periodic blood tests, particularly in the first few months.
Pregnancy Warning
Valsartan carries the FDA’s most serious warning, a black box warning, about use during pregnancy. Drugs that block the angiotensin system can injure or kill a developing fetus, particularly during the second and third trimesters. The risks include impaired kidney development in the fetus, dangerously low amniotic fluid levels, and skeletal abnormalities. If you become pregnant while taking valsartan, it should be stopped as soon as possible. Women who are planning to become pregnant are typically switched to a different type of blood pressure medication beforehand.
The Nitrosamine Contamination Issue
Starting in 2018, certain valsartan products were recalled after testing revealed contamination with nitrosamines, a type of chemical impurity linked to cancer risk at high levels. This wasn’t a problem with valsartan itself but with specific manufacturing processes used by some generic drug makers. The FDA has since established acceptable daily intake limits for nitrosamines and requires manufacturers to test for and control these impurities. As of late 2024, the FDA issued updated guidance tightening requirements for how manufacturers detect and prevent nitrosamine contamination. Valsartan products currently on the market must meet these safety standards, and ongoing recalls are posted on the FDA’s website if any product is found to exceed acceptable levels.
How Valsartan Compares to ACE Inhibitors
Valsartan and ACE inhibitors like lisinopril target the same hormonal system but at different points. ACE inhibitors prevent your body from making angiotensin II in the first place, while valsartan lets it be produced but blocks it from having its effect. In terms of blood pressure control and heart protection, the two classes perform similarly. The practical difference for most people comes down to side effects. Beyond the higher cough risk with ACE inhibitors, the large multinational comparison found no major differences in effectiveness between the two classes for first-line blood pressure treatment. Your doctor may start with one or the other based on cost, tolerability, or your specific health profile.